ReviewBlood2006
Current concepts in the pathophysiology and treatment of aplastic anemia.
Review in Blood, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 9 registered trials, which are not on this map. Cited by 360 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neuropsychological Effects of Immunosuppressive Treatment in Subjects With Aplastic Anemia
A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Aplastic Anemia Patients With Immunosuppressive-Therapy Refractory Thrombocytopenia
Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia
Bone Marrow Mesenchymal Stem Cells in the Treatment of Refractory Severe Acquired Aplastic Anemia
A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Moderate Aplastic Anemia Patients
Low-doses Alemtuzumab and Rituximab Combination as First Line Treatment in Aplastic Anemia
Male Hormones for Telomere Related Diseases
Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia
Male Hormones for Telomere Related Diseases
Who cites it
360 citing papers in PubMed, 3 syntheses or guidelines pooled it, 882 citations in OpenAlex.
- Paroxysmal nocturnal haemoglobinuria in pregnancy-a systematic review with meta analysis.Annals of hematology · 2025Pooled it
- Efficacy of Eltrombopag with Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone on Severe Aplastic Anaemia: A Systematic Review and Meta-analysis.Clinical drug investigation · 2023Pooled it
- Efficacy and Safety of Eltrombopag for Aplastic Anemia: A Systematic Review and Meta-analysis.Clinical drug investigation · 2019Pooled it
- Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study.American journal of hematology · 2026Trial
- Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study.American journal of hematology · 2023Trial
- Combination of umbilical cord mesenchymal stem cells and standard immunosuppressive regimen for pediatric patients with severe aplastic anemia.BMC pediatrics · 2021Trial
- Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias.Blood advances · 2020Trial
- Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag.Blood · 2019Trial
- Interleukin-18 plays a dispensable role in murine and likely also human bone marrow failure.Experimental hematology · 2019Trial
- Circulating S100A8 and S100A9 protein levels in plasma of patients with acquired aplastic anemia and myelodysplastic syndromes.Cytokine · 2019Trial
- T Cell Transcriptomes from Paroxysmal Nocturnal Hemoglobinuria Patients Reveal Novel Signaling Pathways.Journal of immunology (Baltimore, Md. : 1950) · 2017Trial
- Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.The New England journal of medicine · 2017Trial
- Paroxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia.Haematologica · 2015Trial
- Article
- Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management.American journal of hematology · 2026Review
- Favorable Response to Immunosuppressive Therapy in Severe Aplastic Anemia With Trisomy 8 and BCOR Mutation: Sustained Hematologic Response Despite Evolving Mutational Profile-A Case Report.Clinical case reports · 2026Article
- Plasma Elastase Screening in Hematological Disease Reveals Its Potential as a Diagnostic and Prognostic Biomarker in Hematological Malignancies.International journal of laboratory hematology · 2026Article
- Article
- Reconceptualizing Aplastic Anemia-Seed, Worm, Soil.Journal of clinical laboratory analysis · 2026Review
- Immunological links between aplastic anemia and paroxysmal nocturnal hemoglobinuria.International journal of hematology · 2026Review
300 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Aplastic anemia, an unusual hematologic disease, is the paradigm of the human bone marrow failure syndromes. Almost universally fatal just a few decades ago, aplastic anemia can now be cured or ameliorated by stem-cell transplantation or immunosuppressive drug therapy. The pathophysiology is immune mediated in most cases, with activated type 1 cytotoxic T cells implicated. The molecular basis of the aberrant immune response and deficiencies in hematopoietic cells is now being defined genetically; examples are telomere repair gene mutations in the target cells and dysregulated T-cell activation pathways. Immunosuppression with antithymocyte globulins and cyclosporine is effective at restoring blood-cell production in the majority of patients, but relapse and especially evolution of clonal hematologic diseases remain problematic. Allogeneic stem-cell transplant from histocompatible sibling donors is curative in the great majority of young patients with severe aplastic anemia; the major challenges are extending the benefits of transplantation to patients who are older or who lack family donors. Recent results with alternative sources of stem cells and a variety of conditioning regimens to achieve their engraftment have been promising, with survival in small pediatric case series rivaling conventional transplantation results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.